ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Drugs and Targets: EU approves Imbruvica in MCL, CLL

October 24, 2014

Authorization Legislation Still On Congress Busy Agenda, Along With Risk Assessment, Appropriations

February 3, 1984

As von Eschenbach Prepares For New Assignment, NCI’s 2015 Goal Faces Uncertainty. New Strategic Plan Lists Steps to 2015. “The Vision Is Within Our Grasp,” von Eschenbach Says.

March 10, 2006

In Brief: Bertino Moves To MSK As Head Of Chemotherapy Research; Rosemary Clive Laves ACOS For Elm

January 2, 1987

Conversation with The Cancer Letter: IU’s Loehrer Discusses “Business Decision” To Close Bloomington Proton Beam Center

October 17, 2014

Intramural AIDS Vaccine Research Center In Development By NCI, NIAID Scientists

June 13, 1997